Another positive development for Lilly's weight-loss portfolio, with the company reporting positive results from its Phase 3 trial of a once-daily oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist.
Lilly records another win in weight loss in trial of oral GLP-1 agonist
April 22, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 29 August
August 29, 2025 - - Podcast -
Government pressed on diabetes inquiry response as obesity costs soar
August 29, 2025 - - Latest News -
NDIS quarterly report presents a positive picture, but questions remain
August 29, 2025 - - Latest News -
Wesfarmers Health delivers growth as Priceline drives consumer momentum
August 29, 2025 - - Latest News -
'We can evade reality, but we cannot evade the consequences of evading reality'
August 29, 2025 - - Latest News -
Australians fear the loss of independence as vision health concerns rise
August 29, 2025 - - Latest News -
Coalition turns debate on cheaper medicines Bill to HTA reform delays
August 27, 2025 - - Latest News